Bulevirtide (Myrcludex B; MyrB; Hepcludex) is a first-in-class entry inhibitor approved as an antiviral medication for the treatment of chronic hepatitis D. As a novel virion entry inhibitor, Bulevirtide blocks the virion's hepatocyte pathway of entry, the hepatic sodium/taurocholate cotransporting polypeptide (NTCP) receptor. In July 2020 bulevirtide was authorized for use in the E.U. following a positive opinion by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in HDV RNA-positive adult patients with compensated liver disease.

纯度：≥98%

CAS：2012558-47-1